Improved Survival for Multiple Myeloma in Denmark Based on Autologous Stem Cell Transplantation and Novel Drug Therapy in Collaborative Trials: Analysis of Accrual, Prognostic Variables, Selection Bias, and Clinical Behavior on Survival in More Than 1200

详细信息    查看全文

• 作者：Hans E. Johnsen^a ; ^b ; ^haej@rn.dk ; Tobias W. Klausen^a ; Martin Boegsted^b ; Stig Lenhoff^c ; Peter Gimsing^d ; Ilse Christiansen^b ; Tobias Gedde-Dahl^e ; Roald Lindå ; s^f ; Ulf-Henrik Mellqvist^g ; on Behalf of the Nordic Myeloma Study Group
• 关键词：¦Â2-microglobulin ; Blood hemoglobin ; Bone marrow plasma ; European Myeloma Network ; Prognosis
• 刊名：Clinical Lymphoma Myeloma and Leukemia
• 出版年：2010
• 出版时间：August 2010
• 年：2010
• 卷：10
• 期：4
• 页码：290-296
• 全文大小：143 K

文摘

Background

An unexplained survival difference was observed in the Nordic Myeloma Study Group (NMSG) high-dose therapy trial 5/94 in Denmark compared with Sweden and Norway; however, this difference was eliminated in the subsequent NMSG trial 7/98. It was hypothesized that a detailed analysis of potential explanations would reveal important information for future designs of clinical trials for multiple myeloma (MM) patients in Denmark.

Patients and Methods

The analysis is based on 3 consecutive clinical trials coordinated by NMSG from 1990 to 2000: NMSG 4/90 including 583 patients, NMSG 5/94 including 274 patients and NMSG 7/98 including 414 patients with newly diagnosed MM. Event-free and total survival rates were calculated according to the Kaplan-Meier method, and survival comparisons were made by the log-rank test. The Cox proportional hazards regression model was used to estimate the prognostic importance of selected variables.

Results

The analysis revealed no differences in disease stages, prognostic variables, or inclusion bias at diagnosis between the 3 consecutive NMSG trials. However, the number of initial treatment failures was low, and post-relapse survival was superior in Swedish patients as compared to Danish patients. These differences were explained by a defensive clinical practice in Denmark during 1994-1997 for patients with poor risk refractory or relapsed disease.

Conclusion

These initially observed differences were subsequently eliminated most likely as a consequence of international collaboration improving diagnosis, research infrastructure, clinical training, and education as planned within the European Myeloma Network (EMN).